Telix Pharmaceuticals Limited (ASX:TLX)
25.36
+0.89 (3.64%)
May 13, 2025, 4:10 PM AEST
Telix Pharmaceuticals Employees
Telix Pharmaceuticals had 234 employees as of December 31, 2022. The number of employees increased by 76 or 48.10% compared to the previous year.
Employees
234
Change (1Y)
76
Growth (1Y)
48.10%
Revenue / Employee
1.85M AUD
Profits / Employee
118.01K AUD
Market Cap
8.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 234 | 76 | 48.10% |
Dec 31, 2021 | 158 | 149 | 1,655.56% |
Dec 31, 2017 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CSL Limited | 32,698 |
Cochlear | 5,097 |
Sonic Healthcare | 42,000 |
Ramsay Health Care | 90,000 |
Ansell | 15,000 |
Regis Healthcare | 11,000 |
Mesoblast | 73 |
Neuren Pharmaceuticals | 8 |
Telix Pharmaceuticals News
- 5 days ago - Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - GlobeNewsWire
- 5 days ago - Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX - Accesswire
- 6 days ago - ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - Accesswire
- 7 days ago - Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX) - Accesswire
- 10 days ago - Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX) - Accesswire
- 11 days ago - TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation - Accesswire
- 12 days ago - TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited - Accesswire
- 14 days ago - Telix's Illuccix PSMA-PET Imaging Agent Approved in France - GlobeNewsWire